The raised guidance and strong royalty growth signal continued momentum from ENHANZE partnered products. The Dutch patent win against Merck protects a key revenue stream. Watch for further patent developments and partner pipeline progress (12 ENHANZE programs in development).
Drugs in focus
HALO drug pipeline →DARZALEX Faspro
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available since 2020, with multiple FDA-approved indications. No additional regulatory milestones are pending for this specific product.
- Next catalyst
- None dated
What to watchDARZALEX Faspro is an already-approved, commercially mature product with no upcoming binary catalyst for Halozyme. The next stock-moving events for Halozyme are quarterly royalty reports and the Merck Keytruda Qlex patent litigation outcome. Investors should watch J&J's quarterly daratumumab sales figures and Halozyme's Q4 2026 earnings for royalty growth trajectory.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $103.63entry
- T+1 · 8d ago −0.69%α −3.05% · $102.92
- T+5 · 4d ago −3.24%α −5.84% · $100.27
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Halozyme reported Q3 2026 total revenue of $493M (+39% YoY) and non-GAAP EPS of $2.39, beating consensus estimates of $2.36. The company raised its full-year 2026 guidance across all metrics, reflecting strong royalty revenue growth of 44% YoY. A Dutch patent court injunction against Merck's Keytruda Qlex launch in multiple European markets was also announced.
Key Financial Metrics
Key Facts
- Total revenue $493.0M, up 39% YoY from $354.3M
- Royalty revenue $341.0M, up 44% YoY from $236.0M
- Non-GAAP diluted EPS $2.39 vs consensus $2.36 (beat)
- GAAP diluted EPS $2.01 vs $1.43 YoY
- Full-year 2026 guidance raised: total revenue $1.860B-$1.925B, non-GAAP EPS $8.75-$9.05
- Dutch patent court found Merck infringing MDASE patent, granted injunction on Keytruda Qlex in 8 European markets
- Completed $400M in share repurchases in 2026
- Cash and securities $1.08B at quarter end
Financial Impact
Revenue beat consensus by ~$1.4M; guidance raised by $25M-$15M at midpoint for revenue and $0.10-$0.05 for non-GAAP EPS
Risk Factors
- Patent litigation outcomes remain uncertain outside the Dutch ruling
- Reliance on partner product sales for royalty revenue
- Convertible notes increase debt; stockholders' deficit of $55.2M
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001159036-26-000143 |
| Document: halo-20261105.htm | 0001159036-26-000143 |
| Document: 0001159036-26-000143-index-headers.html | 0001159036-26-000143 |
| Document: 0001159036-26-000143-index.html | 0001159036-26-000143 |
| Document: 0001159036-26-000143.txt | 0001159036-26-000143 |
| 8-K Data (Synthetic) | 0001159036-26-000143 |
Track record
15 reports on HALO
1 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +17.70% at T+20 after the Oct 15, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 9, 20268d ago PTAB Trial Bearish 6/10 Entry $102.98 Now $96.50 +6.29% settles Nov 17
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $124.54 to $131.18 Now $96.50 −22.51% ▲ +5.33% +4.62% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $124.83 to $128.50 Now $96.50 −22.69% ▲ +2.94% +3.38% vs SPY
- Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
- Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
- Sep 18, 20268w ago 8-K Mixed 6/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
- Sep 17, 20268w ago Insider Cluster Neutral 2/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $106.12 to $106.92 Now $96.50 −9.07% ▲ +0.75% −0.36% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers